Skip to search formSkip to main contentSkip to account menu

Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations.

TLDR
Current progress in the immunological measurement of the IGF is reviewed including different strategies for avoiding binding protein interference and an attempt is made to indicate circumstances in which the IGFs are exerting their actions in an autocrine/paracrine mode and when endocrine actions predominate.
View on PubMed (opens in a new tab)

Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum.

TLDR
A simplified system of Sm extraction is developed which has permitted a quantitative comparison of native and extracted Sm, and neutral gel filtration studies established that virtually all of the binding complex was removed by acid-ethanol precipitation.
View on PubMed (opens in a new tab)

Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia.

TLDR
The most likely cause of this patient's recurrent hypoglycemia was IGF-II produced by the leiomyosarcoma, and eight months after reoperation, plasma concentrations of IGF-I and IGF-ii were normal, and high-molecular-weight IGF- II was virtually undetectable.
View on PubMed (opens in a new tab)

A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro.

View on PubMed (opens in a new tab)

Somatomedin: Proposed Designation for Sulphation Factor

TLDR
The observations underlying this hypothesis have been amply confirmed and extended and a GH-dependent plasma factor stimulates in cartilage not only the incorporation of sulphate into chondroitin sulphate, but also the incorporate of thymidine into DNA and proline into the hydroxyproline of collagen.
View on Nature (opens in a new tab)

The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors.

View on PubMed (opens in a new tab)

Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.

TLDR
The data suggest that endogenously produced IGF-II functions as an autocrine growth and motility factor in many rhabdomyosarcoma tumors and may be mediated through an alternative signaling pathway.
View on PubMed (opens in a new tab)

Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors.

TLDR
The cause of hypoglycemia in these patients may be the inability of complexes between the abnormal tumor IGF-II and IGFBP-3 to be sequestered in the biologically inactive ternary complex.
View on PubMed (opens in a new tab)

Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.

TLDR
It is concluded that the nonglycosylated big IGF-II of NICTH serum can form normal complexes with serum IGFBPs, and the defective binding in NICTH is attributable to defective IGFBP-3 binding.
View on PubMed (opens in a new tab)

Steroid-protein interactions.

TLDR
The writer shows how the simple words can maximize how the impression of this book is uttered directly for the readers in delivering the presence of the book concept.
View on PubMed (opens in a new tab)
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)